Open access
Sep 2026
Quantitative stability of MGMT promoter methylation in recurrent glioma and implications for temozolomide rechallenge
O^6^-methylguanine–DNA methyltransferase (MGMT) promoter methylation is a key predictive biomarker for temozolomide (TMZ) response in glioma. MGMT status is routinely assessed at diagnosis; however, its utility at recurrence remains incompletely characterized. We aimed to quantify MGMT methylation stability and assess...
H. Noren, Gabriella Pelofsky, Brianna Suffren et al.
· Journal of Neuro-Oncology · 0 citations